WRF
CRSP icon

Waddell & Reed Financial’s CRISPR Therapeutics CRSP Stock Holding History

Waddell & Reed Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$131M Sell
1,071,487
-142,615
-12% -$21.5M 0.27% 108
2020
Q4 		$186M Sell
1,214,102
-98,381
-7% -$11.6M 0.39% 62
2020
Q3 		$110M Buy
1,312,483
+285,151
+28% +$25.3M 0.26% 104
2020
Q2 		$75.5M Buy
1,027,332
+7
+0% +$409 0.2% 136
2020
Q1 		$43.6M Buy
1,027,325
+5
+0% +$258 0.14% 171
2019
Q4 		$62.6M Sell
1,027,320
-19,008
-2% -$1.04M 0.16% 172
2019
Q3 		$42.9M Buy
1,046,328
+44,410
+4% +$2.12M 0.11% 211
2019
Q2 		$47.2M Hold
1,001,918
– – 0.12% 214
2019
Q1 		$35.8M Buy
1,001,918
+1,918
+0.2% +$66.3K 0.09% 266
2018
Q4 		$28.6M Hold
1,000,000
– – 0.08% 277
2018
Q3 		$44.4M Buy
+1,000,000
New +$52.4M 0.1% 239

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Waddell & Reed Financial's CRSP Position: Q1 2021 in Review

Waddell & Reed Financial reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q1 2021, selling an estimated $21.5M and leaving 1,071,487 shares worth $131M. The position accounts for 0.27% of the portfolio, ranked #108.

Waddell & Reed Financial first reported a position in CRSP in Q3 2018 and has held it in 11 quarters since. The position peaked at $186M in Q4 2020. 444 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • Waddell & Reed Financial held 1,071,487 shares of CRISPR Therapeutics worth $131M as of Q1 2021.
  • Waddell & Reed Financial sold 142,615 CRISPR Therapeutics shares in Q1 2021, an estimated $21.5M.
  • CRISPR Therapeutics made up 0.27% of Waddell & Reed Financial's portfolio in Q1 2021, its #108 holding.
  • Waddell & Reed Financial first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 11 quarters since.
  • Waddell & Reed Financial's CRISPR Therapeutics position peaked at $186M in Q4 2020.
  • 444 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.